Idexx Laboratories (IDXX) Cash from Financing Activities (2009 - 2026)

Idexx Laboratories (IDXX) has reported Cash from Financing Activities for 18 consecutive years, with -$211.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 35.99% year-over-year to -$211.4 million; the TTM figure through Mar 2026 stood at -$1.0 billion (up 1.71% YoY), while the FY2025 annual figure was -$1.2 billion, down 32.67% from the prior year.
• Cash from Financing Activities came in at -$211.4 million for Q1 2026 at Idexx Laboratories, up from -$355.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was -$13.5 million in Q1 2022, with the low at -$355.7 million in Q4 2025.
• Average Cash from Financing Activities over 5 years is -$180.4 million, with a median of -$151.0 million recorded in 2023.
• Across the five-year window, Cash from Financing Activities soared 89.6% in 2022 and slumped 983.69% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at -$116.7 million in 2022, then climbed by 12.75% to -$101.8 million in 2023, then plunged by 128.57% to -$232.8 million in 2024, then sank by 52.8% to -$355.7 million in 2025, then soared by 40.56% to -$211.4 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$211.4 million, -$355.7 million, and -$313.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.